Switch theme
Sign up to access all valuation multiples
Fukuda Denshi Co Ltd develops and manufactures medical electronic equipment. The firm operates in four segments: physiological diagnostic equipment, patient monitoring equipment, medical treatment equipment, and consumables and other products. The physiological diagnostic equipment business sells electrocardiographs, vascular screening systems, and blood cell counters. The patient monitoring equipment segment sells patient monitors and transmitters. The medical treatment equipment segment contributes the largest proportion of revenue and sells pacemakers and medical equipment for home treatment. The consumables and other products segment sells disposable electrodes and consumables used for the firm’s devices. Fukuda Denshi generates the vast majority of its sales in Japan.
1948
3.8K+
LTM Revenue $957M
LTM EBITDA $252M
$832M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fukuda Denshi has a last 12-month revenue (LTM) of $957M and a last 12-month EBITDA of $252M.
In the most recent fiscal year, Fukuda Denshi achieved revenue of $963M and an EBITDA of $252M.
Fukuda Denshi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fukuda Denshi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $957M | XXX | $963M | XXX | XXX | XXX |
| Gross Profit | $507M | XXX | $511M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $252M | XXX | $252M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $176M | XXX | $182M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $126M | XXX | $128M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fukuda Denshi's stock price is JPY 6600 (or $45).
Fukuda Denshi has current market cap of JPY 190B (or $1.3B), and EV of JPY 121B (or $832M).
See Fukuda Denshi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $832M | $1.3B | XXX | XXX | XXX | XXX | $4.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fukuda Denshi has market cap of $1.3B and EV of $832M.
Fukuda Denshi's trades at 0.9x EV/Revenue multiple, and 3.3x EV/EBITDA.
Equity research analysts estimate Fukuda Denshi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fukuda Denshi has a P/E ratio of 10.4x.
See valuation multiples for Fukuda Denshi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $832M | XXX | $832M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 3.3x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBIT | 4.7x | XXX | 4.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.4x | XXX | 10.4x | XXX | XXX | XXX |
| EV/FCF | 7.8x | XXX | 12.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFukuda Denshi's last 12 month revenue growth is 2%
Fukuda Denshi's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Fukuda Denshi's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fukuda Denshi's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fukuda Denshi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fukuda Denshi acquired XXX companies to date.
Last acquisition by Fukuda Denshi was XXXXXXXX, XXXXX XXXXX XXXXXX . Fukuda Denshi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fukuda Denshi founded? | Fukuda Denshi was founded in 1948. |
| Where is Fukuda Denshi headquartered? | Fukuda Denshi is headquartered in Japan. |
| How many employees does Fukuda Denshi have? | As of today, Fukuda Denshi has 3.8K+ employees. |
| Is Fukuda Denshi publicy listed? | Yes, Fukuda Denshi is a public company listed on TKS. |
| What is the stock symbol of Fukuda Denshi? | Fukuda Denshi trades under 6960 ticker. |
| When did Fukuda Denshi go public? | Fukuda Denshi went public in 1982. |
| Who are competitors of Fukuda Denshi? | Similar companies to Fukuda Denshi include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Fukuda Denshi? | Fukuda Denshi's current market cap is $1.3B |
| What is the current revenue of Fukuda Denshi? | Fukuda Denshi's last 12 months revenue is $957M. |
| What is the current revenue growth of Fukuda Denshi? | Fukuda Denshi revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Fukuda Denshi? | Current revenue multiple of Fukuda Denshi is 0.9x. |
| Is Fukuda Denshi profitable? | Yes, Fukuda Denshi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fukuda Denshi? | Fukuda Denshi's last 12 months EBITDA is $252M. |
| What is Fukuda Denshi's EBITDA margin? | Fukuda Denshi's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Fukuda Denshi? | Current EBITDA multiple of Fukuda Denshi is 3.3x. |
| What is the current FCF of Fukuda Denshi? | Fukuda Denshi's last 12 months FCF is $106M. |
| What is Fukuda Denshi's FCF margin? | Fukuda Denshi's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Fukuda Denshi? | Current FCF multiple of Fukuda Denshi is 7.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
